JAAHA Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Griffies, J. D.
Right arrow Articles by Griffin, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Griffies, J. D.
Right arrow Articles by Griffin, C. E.
Journal of the American Animal Hospital Association 40:29-41 (2004)
© 2004 American Animal Hospital Association

Original Article

Topical 0.1% Tacrolimus for the Treatment of Discoid Lupus Erythematosus and Pemphigus Erythematosus in Dogs

Joel D. Griffies, DVM, Colleen L. Mendelsohn, DVM, Wayne S. Rosenkrantz, DVM, Diplomate ACVD, Rusty Muse, DVM, Diplomate ACVD, Mona J. Boord, DVM, Diplomate ACVD and Craig E. Griffin, DVM, Diplomate ACVD

From the Animal Dermatology Clinic, 2965 Edinger Avenue, Tustin, California 92780.

Topical 0.1% tacrolimus was used for treatment of localized lesions associated with 10 cases of discoid lupus erythematosus (DLE) and two cases of pemphigus erythematosus (PE) either as a sole therapy (n=2) or as an adjunctive treatment (n=10). Eight of 10 dogs with DLE and both dogs with PE were improved following 8 weeks of topical application. In six of the eight dogs that improved, other medications were discontinued. No adverse effects in clinical or laboratory parameters were noted throughout the study.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Animal Hospital Association.